List of Roxybond drug patents
Roxybond is owned by Protega Pharms.
Roxybond contains Oxycodone Hydrochloride.
Roxybond has a total of 2 drug patents out of which 0 drug patents have expired.
Roxybond was authorised for market use on 20 April, 2017.
Roxybond is available in tablet;oral dosage forms.
The generics of Roxybond are possible to be released after 12 August, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7955619 | PROTEGA PHARMS | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(5 years from now) | |
| US10314788 | PROTEGA PHARMS | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(5 years from now) | |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
ROXYBOND family patents
28
United States
5
Australia
3
Canada
2
Japan
2
China
2
European Union
1
Poland
1
Mexico
1
Spain
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic